Multiple sclerosis more prevalent in Black Americans than previously thought
Multiple sclerosis has traditionally been considered a condition that predominantly affects white people of European ancestry. However, a new analysis conducted by a North American team led by University of Maryland School of Medicine (UMSOM) researchers suggests that the debilitating neurological condition is more prevalent in Black Americans than once thought. It is also far […]
Multiple sclerosis has traditionally been considered a condition that predominantly affects white people of European ancestry. However, a new analysis conducted by a North American team led by University of Maryland School of Medicine (UMSOM) researchers suggests that the debilitating neurological condition is more prevalent in Black Americans than once thought. It is also far more prevalent in Northern regions of the country including New England, the Dakotas, and the Pacific Northwest.
Credit: University of Maryland School of Medicine
Multiple sclerosis has traditionally been considered a condition that predominantly affects white people of European ancestry. However, a new analysis conducted by a North American team led by University of Maryland School of Medicine (UMSOM) researchers suggests that the debilitating neurological condition is more prevalent in Black Americans than once thought. It is also far more prevalent in Northern regions of the country including New England, the Dakotas, and the Pacific Northwest.
Findings from the new study were recently published in the journal JAMA Neurology.
“We found a much higher prevalence of multiple sclerosis in Black Americans than previously thought,” said study corresponding author Mitchell Wallin, MD, MPH, Associate Professor of Neurology at UMSOM. “This helps to confirm the profound impact that healthcare inequities and lack of representation in clinical research have had in terms of driving misconceptions about the prevalence of this disease on historically underserved and underrepresented populations.”
Multiple sclerosis (MS) causes the immune system to attack the central nervous system, specifically the protective layer of myelin that insulates nerve fibers. Symptoms include numbness, tingling, mood changes, memory problems, pain, fatigue, and, in severe cases, blindness or paralysis. In 2019, Dr. Wallin led a team that found the prevalence of multiple sclerosis (MS) in the U.S. to be nearly 1 million people, twice as many as previous estimates.
In the current study, he and his colleagues evaluated three years’ worth of de-identified health insurance claims of 96 million adults to locate adults living with multiple sclerosis. They estimated in more detail how many individuals who are age 18 or older are living with MS in various states and the MS prevalence among people of different races or ethnicities living in specific regions.
The study found strong evidence of a higher prevalence of MS in northern regions of the U.S. compared to southern regions. “Although we don’t know for certain why this is the case, it may have something to do with the spread of viruses in colder climates where people remain indoors more or lower vitamin D levels from less sun exposure,” said Dr. Wallin.
Numerous observational studies have linked low vitamin D levels with an increased risk of MS and with more progressive disease. Other landmark research published in Science found that the common Epstein-Barr virus infection greatly increased the risk for developing MS with a new study out this week demonstrating that antibodies made by the body against the virus attack a vital protein in the brain and spinal cord.
In terms of prevalence of MS within certain sub-groups of Americans, the researchers found a higher prevalence of MS in white people, followed by Black people, “other races,” and then people with Hispanic/Latinx ethnicity. MS occurs in about 4 in 1,000 white people, about 3 in 1,000 Black people, about 2 in 1,000 people of “other races” including Asians, Native Americans, Alaska natives and multi-race individuals, and about 1.5 in 1,000 people of Hispanic/Latinx origin.
The study was funded by the National Multiple Sclerosis Society.
William J. Culpepper, PhD, Adjunct Assistant Professor of Neurology at UMSOM and Associate Director of the Department of Veteran Affairs Multiple Sclerosis Center of Excellence, was a co-author of the study. Faculty at Stanford University School of Medicine, Southern California Permanente Medical Group, University of Manitoba, and University of Alabama also served as co-authors on this study.
“The findings could have a significant impact on public policy makers to help them determine a more equitable allocation of resources towards populations that have been historically under-represented in MS research, and under-recognized when targeting prevention methods and treatment options,” said UMSOM Dean Mark T. Gladwin, MD, Vice President for Medical Affairs, University of Maryland, Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor. “Considering the very diverse patients that we care for across Maryland and in Baltimore, we also have a unique opportunity through the new UM Institute for Health Computing to bring new advances in MS treatment to African American patients who are eligible for the many new biological therapies available.”
Journal
JAMA Neurology
DOI
10.1001/jamaneurol.2023.1135
Method of Research
Observational study
Subject of Research
People
Article Title
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region
Article Publication Date
15-May-2023
COI Statement
Mr Hittle reported grants from the National Institutes of Health (NIH) and personal fees from Institute for Clinical Research during the conduct of the study. Dr Culpepper reported grants from National Multiple Sclerosis Society (NMSS) during the conduct of the study, support from the Veterans Health Administration MS Center of Excellence, and being a member of the NMSS Health Care Delivery and Policy Research study section. Dr Langer-Gould reported being principal investigator for 2 industry-sponsored phase 3 clinical trials (Biogen Idec, Hoffmann-LaRoche) and 1 industry-sponsored observation study (Biogen Idec) and grant support from the NIH, National Institute of Neurological Disorders and Stroke (NINDS), Patient-Centered Outcomes Research Institute, and NMSS. Dr Marrie reported being co-investigator on trials sponsored by Roche and Biogen outside the submitted work; support from the Waugh Family Chair in Multiple Sclerosis; research funding from Canadian Institutes of Health Research, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Consortium of MS Centers, and NMSS; and serving on the editorial board of Neurology. Dr Cutter reported being a member of data and safety monitoring boards for Applied Therapeutics, AI Therapeutics, AstraZeneca, Avexis Pharmaceuticals, AMO Pharmaceuticals, Apotek, Biolinerx, Brainstorm Cell Therapeutics, Bristol Myers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, Immunic, Karuna Therapeutics, Mapi Pharmaceuticals, Modigenetech/Prolor, Merck, Merck/Pfizer, Mitsubishi Tanabe Pharma Holdings, Opko Biologics, Prothena Biosciences, Novartis, Regeneron, Neurim, Sanofi-Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva Pharmaceuticals, National Heart, Lung, and Blood Institute (protocol review committee), Eunice Kennedy Shriver National Institute of Child Health and Human Development (Obstetric-Fetal Pharmacology Research Center oversight committee), University of Texas Southwestern, University of Pennsylvania, and Visioneering Technologies; being a member of consulting or advisory boards for Atara Biotherapeutics, Argenix, Bioeq, Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Klein-Buendel Incorporated, Medimmune, Medday, Novartis, Opexa Therapeutics, Roche, Savara, Somahlution, Teva Pharmaceuticals, Transparency Life Sciences, and TG Therapeutics; receiving personal fees from Alexion, Antisense Therapeutics, Biogen, Clinical Trial Solutions, Entelexo Biotherapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Immunosis, Klein-Buendel Incorporated, Merck/Serono, Novartis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Roche, and SAB Biotherapeutics; and receiving personal fees from Pythagoras (company owned for consulting) outside the submitted work. Dr Kaye reported funding from the Agency for Toxic Substances and Disease Registry, NMSS, and Association for the Accreditation of Human Research Protection Programs. Dr Wagner reported funding from the Agency for Toxic Substances and Disease Registry and NMSS. Dr LaRocca reported being previously employed full-time by the NMSS. Dr Nelson reported grants from the Centers for Disease Control and Prevention, NIH, and NMSS; contracts from the Agency for Toxic Substances and Diseases Registry; compensation for serving as a consultant to Acumen; and being on a data monitoring committee for Neuropace. Dr Wallin reported serving on data safety monitoring boards for the NIH NINDS; being a member of the NMSS Health Care Delivery and Policy Research study section; and receiving funding support from the NMSS and Department of Veterans Affairs Merit Review Research Program. No other disclosures were reported.
What's Your Reaction?